Wednesday, 18 December 2013

Cipla gets US FDA approval for Xopenex

Pharma majors Cipla has received US Food and Drug Administration (US FDA) approval for the generic version of the drug called Xopenex, which is used for asthma. Cipla is the third or the fourth generic company to enter into this space within the US markets.

Moreover, it is a limited opportunity drug and as of December 2012, the drug sales were estimated to be around $439 million.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

No comments:

Post a Comment